application of an amyloid beta oligomer standard in the sfida assay
Clicks: 230
ID: 209709
2016
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
30.0
/100
230 views
34 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #290 of 403 articles by views in Journal of enzyme inhibition and medicinal chemistry
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 403 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Still, there is need for significant improvements in reliable and accurate diagnosis for Alzheimer’s disease (AD) at early stages. It is widely accepted that changes in the concentration and conformation of amyloid-β (Aβ) appear several years before the onset of first symptoms of cognitive impairment in AD patients. Because Aβ oligomers are possibly the major toxic species in AD, they are a promising biomarker candidate for the early diagnosis of the disease. To date, a variety of oligomer-specific assays have been developed, many of them ELISAs. Here, we demonstrate the sFIDA assay, a technology highly specific for Aβ oligomers developed towards single particle sensitivity. By spiking stabilized Aβ oligomers to buffer and to body fluids from control donors, we show that the sFIDA readout correlates with the applied concentration of stabilized oligomers diluted in buffer, cerebrospinal fluid (CSF), and blood plasma over several orders of magnitude. The lower limit of detection was calculated to be 22 fM of stabilized oligomers diluted in PBS, 18 fM in CSF and 14 fM in blood plasma.
| Reference Key |
ekhbach2016frontiersapplication
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Katja eKühbach;Maren eHülsemann;Yvonne eHerrmann;Kateryna eKravchenko;Andreas eKulawik;Christina eLinnartz;Luriano ePeters;Kun eWang;Johannes eWillbold;Dieter eWillbold;Dieter eWillbold;Oliver eBannach;Oliver eBannach |
| Journal | Journal of enzyme inhibition and medicinal chemistry |
| Year | 2016 |
| DOI |
10.3389/fnins.2016.00008
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.